Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

MHRA expands Novo Nordisk's Wegovy (semaglutide) approval to metabolic-associated steatohepatitis with moderate-to-advanced liver fibrosis
Small molecule, metabolic, GLP-1 agonist, MASH, liver fibrosis, semaglutide - Read more

Lotus Pharmaceutical, Henlius' Serpluma (serplulimab) wins MFDS approval for first-line extensive-stage small-cell lung cancer following Ph3 success
Antibody, cancer, monoclonal antibody, small cell lung cancer, PD-1 inhibitor, combination therapy - Read more

Arcturus Therapeutics, Thermo Fisher Scientific collaborate on Phase 3 development and commercialization of ARCT-032 for cystic fibrosis
Manufacturing agreement, rare disease, mRNA, CDMO, commercialization - Read more

Jade Biosciences licenses antibody program from Paragon Therapeutics, up to $22M milestones, $20.1M sublicensing fees
Licensing deal, antibody, milestone payments, royalties - Read more

Genentech, Astex Pharmaceuticals partner on breast cancer small-molecule program, $25M upfront, $490M+ deal
Research collaboration, licensing deal, oncology, small molecule, milestone payments, royalties - Read more

Sanyou Biopharmaceutical, Baiyunshan Xihe partner to co-develop innovative radiopharmaceuticals and radiodiagnostic products for precision oncology
Co-development, radiopharmaceuticals, oncology, AI/ML, drug discovery - Read more

Fosun Pharma, AriBio sign $27.5M equity investment to advance Alzheimer's candidate AR1001 globally
Equity investment, neurological, small molecule, clinical trials, immuno-oncology - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

BridgeBio's Attruby (acoramidis) shows kidney-protective benefits in transthyretin amyloidosis cardiomyopathy Ph3 posthoc analysis
Small molecule, cardiovascular, protein stabilizer, transthyretin amyloidosis cardiomyopathy, cardiorenal protection - Read more

Revolution Medicines reports Ph1/Ph2 data for (zoldonrasib) combinations in metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutation
Small molecule, cancer, KRAS inhibitor, pancreatic cancer, combination therapy - Read more

Brii Bio reports Ph2b end-of-treatment data for BRII-179 and elebsiran combination in chronic hepatitis B virus infection
Protein therapy, infectious disease, hepatitis B, combination therapy, HBsAg functional cure, recombinant protein vaccine - Read more

Treos Bio presents Ph1/2 data showing (PolyPEPI1018) plus anti-PD-L1 remodels tumor microenvironment in microsatellite-stable metastatic colorectal cancer
Vaccine, cancer, peptide vaccine, colorectal cancer, tumor microenvironment, combination therapy - Read more

Scribe Therapeutics files for IPO, advancing lipid-lowering genetic medicines through clinical trials
CRISPR, gene editing, cardiovascular, lipid-lowering, clinical-stage - Read more

Celea Therapeutics raises $180M venture round to advance IPF drug deupirfenidone into late-stage trials
Rare disease, small molecule, pulmonary fibrosis, clinical-stage - Read more

Monash University, Atisama Therapeutics secure $15M MRFF grant for chronic lung disease therapy
Chronic lung disease, clinical-stage, inhaled therapy, small molecule - Read more

ALP Bio raises CHF 150,000 ($186.5K) from Venture Kick to make biologic drugs safer
AI/ML platform, biologic drugs, immunogenicity, preclinical, therapeutic antibodies - Read more

Artan Bio closes $1M Seed round, advancing engineered tRNA therapies for mutation-driven aging
tRNA therapy, preclinical, rare disease, platform technology, gene therapy - Read more

Xellar Biosystems raises $50M in Series A and A+ financing, advancing AI-driven 3D Bio Intelligence platform
AI-driven, drug discovery, organ-on-a-chip, platform technology, machine learning - Read more

United Therapeutics acquires Thymmune Therapeutics for $140M to advance preclinical thymic cell regenerative therapies
Cell therapy, rare disease, strategic, major transaction - Read more

Novartis to acquire Myricx Bio for up to $1.5B, expanding ADC cancer pipeline with novel NMT inhibitor payloads
Antibody-drug conjugate, oncology, strategic, major transaction - Read more

Besins Healthcare acquires UniD Manufacturing to strengthen long-acting drug delivery capabilities in hormonal health
Long-acting drug delivery, hormonal health, strategic, major transaction - Read more

Caris Life Sciences launches AI-powered "Caris Detect" blood test for early multi-cancer detection
Liquid biopsy, oncology, AI-driven diagnostics, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Genentech cuts 103 jobs amid gRED early development restructuring
Operational, drug discovery, cost reduction, strategic - Read more

Amgen recalls nearly 1M heart medication Corlanor bottles due to possible foreign substance contamination
Small molecule, cardiovascular, operational, regulatory - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here